These data as well as research supporting KHDC1L as a novel DUX4 regulated circulating biomarker will be presented in oral and poster presentations at the 32nd Annual FSHD Society International ...

Dux Central are thankful the bar got a waiver for their New Year’s Eve party from noise-intolerant neighbour Sid McAuley.KAI SCHWOERER / Stuff Live music at Dux Central on New Year’s Eve has ...

"These data indicate that by directly targeting DUX4, del-brax may be able to improve the lives of patients with FSHD and potentially meaningfully control their disease. I look forward to ...

FSHD is a rare genetic disease characterized by muscle weakness and wasting due to the activation of the DUX4 gene, affecting thousands of individuals without approved treatments. DYNE-302 targets ...

These findings suggest that preexisting and severe skeletal muscle disease in FSHD has the potential to be reversed by targeting the DUX4 mRNA with DYNE-302. FSHD is a rare, progressive, genetic ...

These findings suggest that preexisting and severe skeletal muscle disease in FSHD has the potential to be reversed by targeting the DUX4 mRNA with DYNE-302. FSHD is a rare, progressive ...

These data as well as research supporting KHDC1L as a novel DUX4 regulated circulating biomarker will be presented in oral and poster presentations at the 32nd Annual FSHD Society International ...

will highlight results on the characterization of a novel DUX4-regulated circulating biomarker in oral and poster presentations -- Avidity cautions readers that statements contained in this press ...

Avidity Biosciences, Inc. (NASDAQ: RNA), a U.S. small & mid-cap biotechnology company, is making significant strides in developing treatments for genetic diseases.With a focus on rare muscular ...